Status:
COMPLETED
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
To confirm that SHVE is a safe and effective procedure and it can prevent bleeding of the hepatic vein. To evaluate the recurrence and metastasis in HCC patients undergoing hepatectomy by SHVE.To eval...
Detailed Description
Hepatocellular carcinoma (HCC), a serious disease with high incidence at home and abroad still shows a rising trend. In recent decade, the overall survival rate of the disease has entered a platform s...
Eligibility Criteria
Inclusion
- Corresponding to diagnostic standards of HCC.
- Patients of liver tumors underwent resection with occlusion of more than one main hepatic veins.
- liver function in the Child-Pugh classification A or B.
- Age between 18\~70 years.
- Haven't taken any current treatment.
- Understanding and being willing to sigh the informed consent form.
Exclusion
- cannot be follow-up
- severe liver, renal, or brain dysfunction
- with tumor thrombi in the main trunk of portal vein
- with tumor thrombi in the hepatic vein
- with extrahepatic metastasis
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT00820339
Start Date
January 1 2009
End Date
November 1 2012
Last Update
April 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China